Molecular Biometrics Announces Results of Parkinson's Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic ...(false negatives. NIR achieved asensitivi...)

"We are greatly encouraged by these results and will continue our research and development efforts to further explore the application of our proprietary technology in the development of an accurate, minimally invasive and cost- effective diagnostic tool for Parkinson's disease," added James T. Posillico, PhD, President and Chief Executive Officer, Molecular Biometrics.

"Spectroscopy of human plasma for diagnosis of idiopathic Parkinson disease," was published in Biomarkers in Medicine (June 2008, Vol. 2, No. 3, Pages 229-238).

Molecular Biometrics was one of six industry research teams to receive a total of $2.7 million in funding granted under The Michael J. Fox Foundation's Therapeutics Development Initiative (TDI) program. TDI is the cornerstone of the Foundation's venture philanthropy efforts to help push promising candidate therapeutics forward in industry pipelines by allowing the Foundation to share the risk of product development.

"We are honored to be a grant recipient of The Michael J. Fox Foundation, and are excited to have our technology recognized for its potential to positively impact the future of PD diagnosis and treatment," said Posillico.

About Parkinson's Disease

Parkinson's disease is a chronic, degenerative neurological disorder that affects one in 100 people over age 60. This degenerative disorder of the central nervous system often affects motor skills and speech, as well as other functions, and is characterized by muscle rigidity, tremor, a slowing of physical movement and, in extreme cases, a loss of physical movement. Parkinson's disease belongs to a group of conditions called movement disorders. While the average age at onset is 60, disease onset starts by age 40 in an estimated five to 10 percent of patients, and people as young as 30 can also be affected. It is estimated
'/>"/>